Definiens announced at the 4th International Definiens Symposium on Harvard Medical School campus the launch of new software that improves productivity in tissue-based research and biomarker development. The new software extends the functionality of Definiens’ existing product portfolio and provides a significant quality control advantage, with up to a two-fold reduction in hands on time for researchers.
Inspired by customer feedback, the software removes a number of bottlenecks in the research process and features end-to-end workflow support from initial image analysis to final results. The efficient whole-slide review along with the smooth integration of image analysis and data mining capabilities significantly reduces hands-on time, increases productivity and accelerates the development of tissue-based biomarkers.
“The latest release of Definiens’ product suite represents the first end-to-end software solution for tissue-based research,” said Kai Hartmann, Director Product Marketing Life Sciences of Definiens. “Definiens customers can now experience the entire workflow process from digital image and metadata to the final result. We are dedicated to continually learn from our users and the discussions at the Symposium are a prime opportunity to obtain inspiration for ongoing product development.”
This latest version of Definiens’ product portfolio is being released at the 4th International Definiens Symposium taking place at the Joseph B. Martin Conference Center on Harvard Medical School campus in Boston, May 13-15, 2013. The Symposium is an annual event featuring more than 20 expert presenters, and represents a unique forum for thought leaders in digital pathology and tissue-based biomarker development to discuss the latest trends in quantitative research and cutting-edge biomedical image and data analysis. The event brings together experts from around the world to share best practices and learn from their approaches and experiences.
“As the leader in image and data analysis solutions for digital pathology, we are proud to be part of the impressive advances in disease diagnosis and patient outcomes being discussed at the 4th International Definiens Symposium,” said Thomas Heydler, CEO of Definiens. “The presentations and discussions highlight that image and data analysis expertise has become the definitive advantage in biomarker development and cancer biology.”